153 related articles for article (PubMed ID: 16472183)
1. Development of miltefosine for the leishmaniases.
Berman JD
Mini Rev Med Chem; 2006 Feb; 6(2):145-51. PubMed ID: 16472183
[TBL] [Abstract][Full Text] [Related]
2. Miltefosine and cutaneous leishmaniasis.
Machado PR; Penna G
Curr Opin Infect Dis; 2012 Apr; 25(2):141-4. PubMed ID: 22248979
[TBL] [Abstract][Full Text] [Related]
3. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
4. Current treatment approaches to leishmaniasis.
Berman J
Curr Opin Infect Dis; 2003 Oct; 16(5):397-401. PubMed ID: 14501991
[TBL] [Abstract][Full Text] [Related]
5. Miltefosine: issues to be addressed in the future.
Berman J; Bryceson AD; Croft S; Engel J; Gutteridge W; Karbwang J; Sindermann H; Soto J; Sundar S; Urbina JA
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S41-4. PubMed ID: 16750231
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine: an oral drug for visceral leishmaniasis.
Prasad R; Kumar R; Jaiswal BP; Singh UK
Indian J Pediatr; 2004 Feb; 71(2):143-4. PubMed ID: 15053378
[TBL] [Abstract][Full Text] [Related]
7. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
8. Broad Spectrum and Safety of Oral Treatment with a Promising Nitrosylated Chalcone in Murine Leishmaniasis.
Sousa-Batista AJ; Escrivani-Oliveira D; Falcão CAB; Philipon CIMDS; Rossi-Bergmann B
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012761
[TBL] [Abstract][Full Text] [Related]
9. Miltefosine to treat leishmaniasis.
Berman J
Expert Opin Pharmacother; 2005 Jul; 6(8):1381-8. PubMed ID: 16013987
[TBL] [Abstract][Full Text] [Related]
10. Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis.
Fischer C; Voss A; Engel J
Med Microbiol Immunol; 2001 Nov; 190(1-2):85-7. PubMed ID: 11770118
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
12. Treatment of leishmaniasis with miltefosine: 2008 status.
Berman JJ
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
[TBL] [Abstract][Full Text] [Related]
13. An update on the clinical pharmacology of miltefosine in the treatment of leishmaniasis.
Palić S; Beijnen JH; Dorlo TPC
Int J Antimicrob Agents; 2022 Jan; 59(1):106459. PubMed ID: 34695563
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine for visceral leishmaniasis.
Eibl H
N Engl J Med; 2000 Mar; 342(12):894-5. PubMed ID: 10733376
[No Abstract] [Full Text] [Related]
15. Miltefosine: great expectations against visceral leishmaniasis.
More B; Bhatt H; Kukreja V; Ainapure SS
J Postgrad Med; 2003; 49(1):101-3. PubMed ID: 12865588
[No Abstract] [Full Text] [Related]
16. Clinical status of agents being developed for leishmaniasis.
Berman J
Expert Opin Investig Drugs; 2005 Nov; 14(11):1337-46. PubMed ID: 16255674
[TBL] [Abstract][Full Text] [Related]
17. Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Sindermann H; Croft SL; Engel KR; Bommer W; Eibl HJ; Unger C; Engel J
Med Microbiol Immunol; 2004 Nov; 193(4):173-80. PubMed ID: 14513375
[TBL] [Abstract][Full Text] [Related]
18. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients.
Marques N; Sá R; Coelho F; Oliveira J; Saraiva Da Cunha J; Meliço-Silvestre A
Scand J Infect Dis; 2008; 40(6-7):523-6. PubMed ID: 18584541
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.
Palić S; Bhairosing P; Beijnen JH; Dorlo TPC
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31036692
[TBL] [Abstract][Full Text] [Related]
20. [Leishmaniasis--oral treatment with hexadecylphosphocholine].
Bommer W; Eibl HJ; Engel KR; Kuhlencord A; Sindermann H; Sundar S; Zappel H
Wien Klin Wochenschr; 2004; 116 Suppl 4():24-9. PubMed ID: 15683039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
